Gyre Therapeutics (GYRE) Net Cash Flow (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Net Cash Flow of $166000.0 for Q1 2026, down 94.78% year-over-year from $3.2 million in Q1 2025, and up 104.85% quarter-over-quarter from -$3.4 million in Q4 2025.
Gyre Therapeutics (GYRE) Net Cash Flow (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Net Cash Flow for 17 consecutive years, with $166000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow fell 94.78% year-over-year to $166000.0; the TTM figure through Mar 2026 stood at $21.9 million (up 250.37% YoY), while the FY2025 annual figure was $24.9 million, up 216.3% from the prior year.
- Net Cash Flow climbed to $166000.0 in Q1 2026 per GYRE's latest filing, from -$3.4 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $40.6 million in Q2 2022 and bottomed at -$52.3 million in Q3 2022.
- Historically, Net Cash Flow has averaged -$2.1 million across 5 years, with a median of -$3.4 million in 2025.
- Annual changes were most pronounced in 2022 — Net Cash Flow slumped 261.62% — and 2025, when it soared 1203.26%.
- Gyre Therapeutics' Net Cash Flow stood at -$26.9 million in 2022, then jumped by 174.15% to $19.9 million in 2023, then plunged by 119.05% to -$3.8 million in 2024, then grew by 9.85% to -$3.4 million in 2025, then jumped by 104.85% to $166000.0 in 2026.
- Business Quant data shows GYRE's Net Cash Flow at $166000.0 in Q1 2026, -$3.4 million in Q4 2025, and $3.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | -7.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.00 Mn |
| Jun 30, 2026 | -7.00 Mn |
| Mar 31, 2026 | 166,000.00 |
| Mar 31, 2026 | 166,000.00 |
| Dec 31, 2025 | -3.42 Mn |
| Dec 31, 2025 | -3.42 Mn |
| Sep 30, 2025 | 3.72 Mn |
| Sep 30, 2025 | 3.72 Mn |
| Jun 30, 2025 | 21.44 Mn |
| Jun 30, 2025 | 21.44 Mn |
| Mar 31, 2025 | 3.18 Mn |
| Mar 31, 2025 | 3.18 Mn |
| Dec 31, 2024 | -3.80 Mn |
| Dec 31, 2024 | -3.80 Mn |
| Sep 30, 2024 | -337,000.00 |
| Sep 30, 2024 | -337,000.00 |
| Jun 30, 2024 | -13.61 Mn |
| Jun 30, 2024 | -13.61 Mn |
| Mar 31, 2024 | -3.68 Mn |
| Mar 31, 2024 | -3.68 Mn |